Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma-Reference-Cited by-同舟云学术

Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma

Published:2021-06 Issue:6 Volume:2 Page:100178
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Nakagawa Kazuhiko,Kijima Takashi,Okada Morihito,Morise Masahiro,Kato Motoyasu,Hirano Katsuya,Fujimoto Nobukazu,Takenoyama Mitsuhiro,Yokouchi Hiroshi,Ohe Yuichiro,Hida Toyoaki,Aoe Keisuke,Kishimoto Takumi,Hirokawa Masato,Matsuki Hironori,Kaneko Yutaro,Yamada Taketo,Morimoto Chikao,Takeda Masayuki

Funder

Kissei Pharmaceutical Co Ltd

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. MPM: malignant pleural mesothelioma;Cao;Ann Cardiothorac Surg,2012

2. Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database;van Gerwen;Carcinogenesis,2019

3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: malignant pleural mesothelioma. version 1.2019. http://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf. Accessed April 4, 2020.

4. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT);Okada;Clin Cancer Res,2019

5. A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9–15) PROMISE-meso trial;Popat;Ann Oncol,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malignant Pleural Mesothelioma: Socioeconomic and Clinical Aspects;Current Cancer Therapy Reviews;2024-07-23

2. HDAC Inhibition Induces CD26 Expression on Multiple Myeloma Cells via the c-Myc/Sp1-mediated Promoter Activation;Cancer Research Communications;2024-02-09

3. Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies;Cells;2023-08-14

4. Association of Dipeptidylpeptidase 4 (CD26) With Chondrocyte Senescence and Radiographic Progression in Knee Osteoarthritis;Arthritis & Rheumatology;2023-04-23

5. Immunotherapy vs. Chemotherapy in Subsequent Treatment of Malignant Pleural Mesothelioma: Which Is Better?;Journal of Clinical Medicine;2023-03-27